The association of PD-L1 gene polymorphisms with non-small-cell lung cancer susceptibility and clinical outcomes in a Chinese population.

Objective To investigate the influence of PD-L1 polymorphisms on the susceptibility of non-small-cell lung cancer (NSCLC) and the prognosis of NSCLC patients who undergo platinum-based chemotherapy. Materials and methods 9 single nucleotide polymorphisms (SNPs) in the PD-L1 gene, including rs822336 (G>C), rs822337 (T>A), rs10815225 (G>C), rs7866740 (C>G), rs866066 (C>T), rs822338 (C>T), rs2890657 (C>G), rs2890658 (C>A), and rs229136 (C>G) were selected for this study. Genotyping was performed in 281 advanced NSCLC patients and 251 healthy volunteers using the matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) method. Results The G allele of PD-L1 rs7866740 was significantly related to the risk of NSCLC. Compared with the C allele, the G allele an increase the risk of NSCLC (OR=3.532, 95% CI: 1.232-10.129, P=0.001). In terms of the clinical outcomes, PD-L1 rs2890658 C>A was significantly associated with both a worse progression-free survival (adjusted HR=1.367, 95% CI=1.0-1.8, P=0.038) and a worse overall survival (adjusted HR=1.402, 95% CI=1.0-1.9, P=0.026) of NSCLC patients. PD-L1 rs822336 G>C was significantly related to a worse overall survival (adjusted HR=1.393, 95% CI=1.1-1.8, P=0.021). Conclusions PD-L1 rs7866740 C>G may play a role in the pathogenesis of NSCLC. PD-L1 rs2890658 C>A and rs822336 G>C are related to the prognoses of patients receiving platinum-based chemotherapy.